Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer
March 21 2023 - 3:05PM
Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical), a women's
health company focused on solutions to meet the distinct uterine
healthcare needs of women, announced today the appointment of Kaile
Zagger as its new Chief Commercial Officer. Ms. Zagger’s leadership
will help guide the strategic growth of the company and advance its
position as a leader in women’s healthcare solutions.
“We are excited to have Kaile as our new Chief Commercial
Officer for her proven track record of driving exponential growth
and productivity, while delivering bottom line results,” said Todd
Usen, president and CEO of Minerva Surgical. “Beyond her
professional acumen, Ms. Zagger's passion for channeling her
leadership experience into companies that improve the quality of
healthcare for women and children aligns with our mission at
Minerva Surgical, and we are pleased to welcome her to the
team.”
Ms. Zagger brings more than 20 years of experience in the
healthcare industry in sales, organizational development, growth
acceleration, restructuring and operational excellence with
increasing responsibility at such firms as Boston Scientific,
Intuitive Surgical, GE Healthcare, Philips Healthtech and Change
Healthcare. Additionally, she has held C-Suite positions for both
private and publicly-held companies and has led multiple
large-scale transformations.
“Women’s health is a uniquely personal field of healthcare that
I am committed to transforming,” said Kaile Zagger. “It is an
important time in women’s health, and we have much work to do to
progress this area of care. I am excited about the future and
thrilled to work alongside this management team to re-position the
organization as a leader in this important segment.”
In addition to her executive level leadership with globally
recognized firms, Ms. Zagger has served as a board member for
private organizations and nonprofits. Beyond her professional
career, Ms. Zagger is the co-Founder of a non-profit foundation
whose mission is eradication of late-stage female reproductive
cancers.
About Minerva Surgical, Inc.
Minerva Surgical is a commercial-stage medical technology
company focused on developing, manufacturing, and commercializing
minimally invasive solutions to meet the distinct uterine
healthcare needs of women. The Company has established a broad
product line of commercially available, minimally invasive
alternatives to hysterectomy, which are designed to address the
most common causes of Abnormal Uterine Bleeding (AUB) in most
uterine anatomies. The Minerva Surgical solutions can be used in a
variety of medical treatment settings and aim to address the
drawbacks associated with alternative treatment methods and to
preserve the uterus by avoiding unnecessary hysterectomies.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements are based on management’s
current assumptions and expectations of future events and trends,
which affect or may affect the Company’s business, strategy,
operations or financial performance, and actual results may differ
materially from those expressed or implied in such statements due
to numerous risks and uncertainties. Forward-looking statements may
include information regarding trends and expectations for the
Company’s products and technology in the future, and the Company’s
expected future financial performance. Forward-looking statements
are inherently subject to risks and uncertainties, some of which
cannot be predicted or quantified. Factors that could cause actual
results to differ materially from those contemplated in this press
release can be found in the Risk Factors section of the Company’s
quarterly report on Form 10-Q for the quarter ended September 30,
2022, as filed with the U.S. Securities and Exchange Commission
(SEC) on November 14, 2022, and available at www.SEC.gov, and which
will be updated in our 2022 Annual Report on Form 10-K which we
expect to file with the SEC on March 22, 2023. Because
forward-looking statements are inherently subject to risks and
uncertainties, you should not rely on these forward-looking
statements as predictions of future events. All statements other
than statements of historical fact are forward-looking statements.
Except to the extent required by law, the Company undertakes no
obligation to update or review any estimate, projection, or
forward-looking statement. Actual results may differ from those set
forth in this press release due to the risks and uncertainties
inherent in the Company’s business.
MEDIA CONTACT
media@minervasurgical.com
INVESTOR RELATIONS CONTACT
Investor.relations@minervasurgical.com
RELATED LINKS
https://www.aubandme.com https://www.minervasurgical.com
Minerva Surgical (NASDAQ:UTRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Minerva Surgical (NASDAQ:UTRS)
Historical Stock Chart
From Jul 2023 to Jul 2024